Balance Sheet
Cash Flow Statement
AcquisitionsAmortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Dividends Paid - CommonFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based CompensationShares RepurchasedShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Viemed Healthcare (VMD) Share-based Compensation (2018 - 2025)

Viemed Healthcare's Share-based Compensation history spans 8 years, with the latest figure at $2.3 million for Q4 2025.

  • For Q4 2025, Share-based Compensation rose 51.22% year-over-year to $2.3 million; the TTM value through Dec 2025 reached $9.1 million, up 45.3%, while the annual FY2025 figure was $9.1 million, 45.3% up from the prior year.
  • Share-based Compensation reached $2.3 million in Q4 2025 per VMD's latest filing, up from $2.2 million in the prior quarter.
  • In the past five years, Share-based Compensation ranged from a high of $2.3 million in Q2 2025 to a low of $1.2 million in Q2 2021.
  • Average Share-based Compensation over 5 years is $1.6 million, with a median of $1.4 million recorded in 2023.
  • Peak YoY movement for Share-based Compensation: decreased 0.85% in 2024, then skyrocketed 61.38% in 2025.
  • A 5-year view of Share-based Compensation shows it stood at $1.3 million in 2021, then increased by 0.92% to $1.3 million in 2022, then increased by 16.48% to $1.5 million in 2023, then decreased by 0.85% to $1.5 million in 2024, then soared by 51.22% to $2.3 million in 2025.
  • Per Business Quant, the three most recent readings for VMD's Share-based Compensation are $2.3 million (Q4 2025), $2.2 million (Q3 2025), and $2.3 million (Q2 2025).